

# CBL0137 hydrochloride

Catalog No: tcsc0033711



## Available Sizes

---

**Size:** 2mg

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg



## Specifications

---

**CAS No:**

1197397-89-9

**Formula:**

$C_{21}H_{25}ClN_2O_2$

**Pathway:**

Apoptosis;NF-κB

**Target:**

MDM-2/p53;NF-κB

**Purity / Grade:**

>98%

**Solubility:**

H<sub>2</sub>O : 15.2 mg/mL (40.76 mM; Need ultrasonic and warming); DMSO : 30 mg/mL (80.45 mM; Need ultrasonic and warming)

**Alternative Names:**

Curaxin-137 hydrochloride;CBL-C137 hydrochloride

**Observed Molecular Weight:**

372.89

**Product Description**


CBL0137 hydrochloride is an inhibitor of the histone chaperone, **FACT**. CBL0137 hydrochloride can also activate **p53** and inhibits **NF-κB** with **EC<sub>50</sub>**s of 0.37 and 0.47 μM, respectively.

IC50 & Target: FACT<sup>[1]</sup>

EC50: 0.37 μM (p53), 0.47 μM (NF-Kb)<sup>[2]</sup>

**In Vitro:** Treatment with CBL0137 hydrochloride leads to complete absence of living cells at concentrations above 2.5 μM. CBL0137 hydrochloride causes a greater reduction in the number of colonies formed of not only MiaPaCa-2 cells when combines with gemcitabine, but also gemcitabine-resistant PANC-1 cells. Treatment of human pancreatic cancer cells with CBL0137 hydrochloride results in a dose dependent reduction of protein and mRNA levels of RRM1 and RRM2<sup>[1]</sup>.

**In Vivo:** The CBL0137 hydrochloride monotherapy group and the CBL0137 hydrochloride-gemcitabine combination group samples show large necrotic fields, numerous apoptotic bodies and loss of tumor cells. Sub-optimal doses of 50 to 60 mg/kg CBL0137 hydrochloride causes similar enhancement of gemcitabine antitumor activity as that produced by the maximum tolerated dose (MTD) of 90 mg/kg as indicated by the lack of statistically significant differences among the combination groups. CBL0137 hydrochloride inhibits FACT function through depletion of the pool of active FACT involved in transcription elongation<sup>[1]</sup>. CBL0137 hydrochloride, given by oral gavage at a nontoxic dose of 30 mg/kg per day on a 5 days on/2 days off schedule, suppresses tumor growth in xenografts of colon (DLD-1), renal cell carcinoma (Caki-1), and melanoma (Mel-7) tumor cell lines and transplanted surgical samples from patients with pancreatic ductal adenocarcinoma<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!